Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified · Recurrent Primary Mediastinal Large B-Cell Lymphoma · Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified · Refractory Primary Mediastinal Large B-Cell Lymphoma · Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • City of Hope Medical Center, Duarte, California, United States

    Contact: Study coordinator (Geoffrey Shouse) · gshouse@coh.org · 626-239-5289
    Contact: Principal Investigator (Geoffrey Shouse)
  • City of Hope Atlanta Cancer Center, Newnan, Georgia, United States

    Contact: Study coordinator (Geoffrey Shouse) · gshouse@coh.org · 626-239-5289
    Contact: Principal Investigator (Geoffrey Shouse)
  • City of Hope at Chicago, Zion, Illinois, United States

    Contact: Study coordinator (Geoffrey Shouse) · gshouse@coh.org · 626-239-5289
    Contact: Principal Investigator (Geoffrey Shouse)
Study leads
  • Geoffrey Shouse

    Principal Investigator

    City of Hope Medical Center